SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAVAZZINI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.257
EU - Europa 2.448
AS - Asia 2.122
OC - Oceania 8
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 4
Totale 13.850
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.235
CN - Cina 1.081
DE - Germania 577
UA - Ucraina 511
TR - Turchia 467
IT - Italia 443
SG - Singapore 427
GB - Regno Unito 277
SE - Svezia 202
FI - Finlandia 129
FR - Francia 78
PL - Polonia 62
RU - Federazione Russa 59
ID - Indonesia 55
BE - Belgio 41
CZ - Repubblica Ceca 29
CA - Canada 22
VN - Vietnam 22
IN - India 17
HK - Hong Kong 16
JP - Giappone 15
LT - Lituania 8
AU - Australia 7
NL - Olanda 7
IE - Irlanda 6
EU - Europa 5
IR - Iran 5
BR - Brasile 4
IL - Israele 4
KR - Corea 4
AT - Austria 2
BG - Bulgaria 2
DK - Danimarca 2
EG - Egitto 2
ES - Italia 2
KZ - Kazakistan 2
PK - Pakistan 2
PT - Portogallo 2
RO - Romania 2
BD - Bangladesh 1
BO - Bolivia 1
CH - Svizzera 1
CO - Colombia 1
DZ - Algeria 1
EE - Estonia 1
GR - Grecia 1
HU - Ungheria 1
MK - Macedonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
RW - Ruanda 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 13.850
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.238
Fairfield 1.181
Houston 814
Chandler 648
Jacksonville 625
Ashburn 541
Ann Arbor 487
Seattle 451
Wilmington 424
Cambridge 379
Santa Clara 349
Beijing 342
Singapore 341
Izmir 226
Nanjing 199
Princeton 170
Ferrara 153
New York 122
Boardman 118
San Diego 112
Shanghai 95
Addison 90
Milan 73
Shenyang 67
Nanchang 63
Warsaw 60
Jakarta 55
Los Angeles 53
Bremen 45
Hebei 45
Brussels 41
Falls Church 33
London 32
Redwood City 32
Changsha 30
Jinan 29
Tianjin 29
Jiaxing 27
Munich 26
Mountain View 23
Brno 22
Dong Ket 22
Dearborn 21
Zhengzhou 21
Norwalk 19
Des Moines 17
Hong Kong 15
San Mateo 15
Guangzhou 14
Kunming 14
Ningbo 14
Frankfurt am Main 13
Orange 13
San Jose 13
Toronto 13
Auburn Hills 12
Hefei 12
Helsinki 12
Leawood 12
Tappahannock 11
Indiana 10
Washington 10
Florence 9
Bologna 8
Chicago 8
Fuzhou 8
Taizhou 8
Hangzhou 7
Ottawa 7
Rome 7
San Francisco 7
Augusta 6
Dublin 6
Kilburn 6
Okayama 6
Philadelphia 6
Redmond 6
Siena 6
Lappeenranta 5
Monza 5
Olomouc 5
Chengdu 4
Haikou 4
Lanzhou 4
Minerbe 4
Monmouth Junction 4
Palermo 4
Torino 4
Acton 3
Ahmedabad 3
Changchun 3
Chiswick 3
Edinburgh 3
Hounslow 3
Illasi 3
Kobe 3
Lagopesole 3
Newark 3
Simi Valley 3
Stockholm 3
Totale 10.383
Salva come PNG Salva come JPEG
Nome #
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI 189
Diagnostic work-up for clinical and prognostic assessment of acute leukaemia 164
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death 163
Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 143
Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype 139
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 137
Acute Human Herpesvirus-6A infection of human mesothelial cells modulates HLA molecules 137
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients 136
Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in SplenicMarginal Zone Lymphoma 136
Secondary chromosome changes in mantle cell lymphoma: cytogenetic and fluorescence in situ hybridization studies. 133
Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients 133
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. 132
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy 132
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: Clinical and biological correlations 132
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 131
CYTOGENETIC ABERRATIONS IN THE CD38 POSITIVE FRACTION OF CD38 NEGATIVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: A MARKER OF AGGRESSIVENESS? 129
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype 127
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 126
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 125
null 124
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 122
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis 119
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations 119
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 118
Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features. 116
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 116
Hepatosplenic T-cell lymphoma (HSTCL). 115
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 115
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 115
A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma 115
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia 114
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 114
Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations (J Hematol Oncol. (2016) 9 (88) DOI:10.1186/s13045-016-0320-z) 113
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 112
Myelofibrosis with Myeloid Metaplasia (MMM)/Idiopathic myelofibrosis/Agnogenic myeloid metaplasia 112
Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival 111
Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13) PDGFRB-NDE1 fusion 109
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 109
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays 109
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. 109
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 108
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB 107
PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements 106
B-Cell chronic lymphocytic leukemia (B-CLL) with 14q32 translocations: haematological features and clinical outcome. 106
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 106
Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. 106
Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma. 105
THE EUTOS LONG-TERM SURVIVAL SCORE IS PREDICTIVE FOR RESPONSE AND OUTCOME IN CML PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 105
Detection of inherited chromosomally integrated HHV-6 (ciHHV-6) in a marker chromosome 104
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. 103
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 103
Intestinal T-cell lymphoma 102
“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia” 102
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 101
Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biological significance 100
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) 100
The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients. 100
null 100
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 100
Four novel non-random chromosome rearrangements in B-cell chronic lymphocytic leukaemia: 6p24-25 and 12p12-13 translocations, 4q21 anomalies and monosomy 21 98
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: Correlations with clinicobiologic parameters 97
APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS 96
Chromosome Aberrations by Conventional Karyotyping in Chronic Lymphocytic Leukemia Carrying No Aberration by Fluorescence in Situ Hybridization: Correlation with Prognostic Parameters and Clinical Features 96
Alterazioni cromosomiche in cellule staminali emopoietiche indotte da esposizioni ambientali o professionali. 95
Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases 95
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated with Ibrutinib 95
VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY? 95
Abnormalities of chromosomes 1p34-36, 4p16, 4q35, 9q11-32 and +7 represent novel recurrent cytogenetic rearrangements in chronic lymphocytic leukemia 95
Identifying High-Risk Chronic Lymphocytic Leukemia: A Reappraisal of the Impact of Prognostic and Predictive Factors 94
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 94
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. 93
EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB 93
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 92
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 90
Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome 90
IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB 90
Essential Thrombocythemia (ET) 90
Imatinib In Very Elderly CML Patients: What Can We Achieve? 88
CHROMOSOME ABNORMALITIES ADDITIONAL TO THE PHILADELPHIA CHROMOSOME AT THE DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA. PATHOGENETIC AND PROGNOSTIC IMPLICATIONS. 88
Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia 88
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 88
null 88
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. 88
Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party 87
A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line 86
Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis 86
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia 86
null 85
Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. 83
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? 83
TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA 83
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 82
Clonal evolution in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 82
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study 80
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 79
null 78
null 78
Differences among young adults, adults and elderly chronic myeloid leukemia patients 78
Significato dell'analisi citogenetica e citogenetico-molecolare nella diagnosi e nella prognosi delle neoplasie ematologiche. Cytogenetics and molecular cytogenetics in diagnosis and prognosis of haematological malignancies 77
LONG-TERM OUTCOME TO FIRST-LINE IMATINIB ACCORDING TO 2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA: A GIMEMA CML WP ANALYSIS 76
Totale 10.619
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.117
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.505
Totale 73.622
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.885 0 0 0 0 209 357 277 292 259 299 135 57
2020/20212.170 141 149 91 207 121 200 71 241 41 322 396 190
2021/20221.647 129 188 54 59 84 112 93 97 44 137 163 487
2022/20231.579 180 88 64 182 259 209 74 167 210 7 89 50
2023/2024780 79 91 37 18 38 143 42 54 24 16 26 212
2024/20251.028 94 102 273 101 458 0 0 0 0 0 0 0
Totale 14.137